Nattokinase and heart health: the clotting-marker story isn't a prevention story
Table of Contents
A supplement can change a blood test without stopping a heart attack. That’s the gap in the nattokinase pitch. The enzyme has shown activity against fibrin in lab work, and a tiny human experiment found short-lived changes in clotting-related markers. But the longer randomized trial looking at artery measurements didn’t find a benefit. Those aren’t interchangeable results - one asks whether something happens in a sample, the other whether it changes a measured risk factor over years. Neither proves that a capsule prevents clots or cardiovascular events. (Mechanism review; single-dose study; three-year trial)
There’s a smaller, more interesting blood-pressure signal in the research. It deserves a look, not a leap to “natural blood thinner.” And if you’re already taking a medicine to prevent clots, the gap between those two ideas is a safety issue, not a semantic quibble. (2023 review; Memorial Sloan Kettering Cancer Center)
The enzyme, the food and the blood-thinner label #
Nattokinase is an enzyme associated with natto, the fermented soybean food. A capsule containing isolated nattokinase isn’t the same thing as a serving of natto, and the food’s history doesn’t establish that a supplement prevents disease. “Natural blood thinner” is tempting shorthand. It also makes the product sound like a tested, controllable substitute for an anticoagulant or antiplatelet medicine. It isn’t. (MSKCC; mechanism review)
In lab and animal research, the enzyme acts on fibrin, part of the mesh in a blood clot. That tells us why researchers became interested. It doesn’t tell us that swallowed nattokinase safely dissolves a clot in a person. In a crossover experiment involving 12 healthy young men, one oral dose shifted several fibrinolysis and coagulation markers for a short time; the measured values remained within normal ranges. No one in that experiment was being treated for a clot. No heart attacks or strokes were prevented by a lab result. (Mechanism review; single-dose experiment)
What changed in the human trials? #
Blood pressure, perhaps. A systematic review of randomized studies found an average reduction of roughly 3.45 mmHg in systolic and 2.32 mmHg in diastolic pressure in its blood-pressure analysis. That’s a pool of three trials and 223 people, not every participant across the review. One eight-week trial also reported a lower blood pressure relative to placebo. But short trials and modest averages don’t predict what any one person’s reading will do, let alone whether they’ll avoid a stroke.
Then there’s the longer test. In a placebo-controlled study that randomized 265 generally healthy, low-risk adults and followed them for a median of three years, nattokinase didn’t significantly slow carotid artery-wall thickening or improve blood pressure and other measured outcomes. That study doesn’t settle every question about other populations or formulations. But it does make a broad “heart protection” claim hard to defend. The short blood-pressure studies and the longer null trial point in different directions; we can’t tidy that up by declaring one of them the winner.
Plaque claims need a different caution. A retrospective analysis of 1,062 selected records reported favorable before-and-after carotid and lipid measurements. It wasn’t a randomized placebo comparison, so changes over time could reflect other factors. Size alone doesn’t fix that. Nor does the analysis establish a safe high dose or support combining nattokinase with aspirin.
And don’t credit a blend’s result to one ingredient. A small trial found lipid effects with nattokinase plus red yeast rice, not a comparable effect from nattokinase alone on the key lipid measures. A 2026 expert commentary about a larger natto/red yeast rice study flags the same problem: without a nattokinase-only arm, you can’t separate its contribution. The randomized-trial review also found inconsistent lipid results. So none of this demonstrates fewer heart attacks, strokes or blood clots from isolated nattokinase in the evidence reviewed here.
The part to discuss before opening a bottle #
A possible interaction can matter even when its exact frequency isn’t known. MSKCC cautions against nattokinase for people with clotting disorders and warns about potential bleeding when it’s taken with anticoagulants, antiplatelets or clot-dissolving medicines. If you take warfarin, apixaban, rivaroxaban, aspirin, clopidogrel or another medicine affecting clotting, ask your prescriber or pharmacist about the actual product and your full medication list before adding it. Don’t stop a prescribed drug to make room for a supplement.
One published case report describes a cerebellar hemorrhage in a person taking aspirin and nattokinase who also had cerebral microbleeds. Another report describes fatal internal bleeding after a fall and a ruptured liver cyst in an older person whose nattokinase intake was uncertain. They’re warnings to take seriously, not proof of a general bleeding rate or proof that the supplement caused the rupture or death. Equally, a small trial without a serious bleed can’t establish safety for everyone.
Replacement is a separate danger. A published report describes mechanical heart-valve thrombosis after a patient substituted nattokinase for warfarin. It’s a case, not a head-to-head trial, but it illustrates why a valve patient shouldn’t try to run anticoagulation by supplement label. The same no-substitution rule applies if you’re being treated for atrial fibrillation, vascular disease or a past clot. If a clot is suspected now, get medical assessment instead of experimenting with nattokinase. (MSKCC)
Surgery coming up? Tell the surgeon, anesthesia team and prescribing clinician about every supplement and clot-affecting medicine you use. The FDA notes that some supplements alter bleeding risk around procedures and that clinicians sometimes advise stopping them ahead of time. That’s general guidance, not a validated nattokinase stop date. Let your team decide what to do; never pause prescribed blood thinners on your own.
There are other gaps, too. We don’t have good safety data for nattokinase supplements in pregnancy, breastfeeding or children; people with soy or natto allergy shouldn’t assume a capsule is harmless. Older adults, people with kidney disease or bleeding disorders, and anyone juggling several medicines have particularly good reasons to get an individual review. Product composition and testing can vary, and supplements don’t go through the same premarket effectiveness review as medicines. (NCCIH on supplements; review noting an allergy report; MSKCC)
What I’d take to the appointment #
I’d bring the bottle (or a photo of its label), the rest of my supplement list and the name of every prescription drug. Then I’d ask: What’s the health outcome I’m trying to change? Is there evidence this product changes that outcome in someone with my history? Could it complicate my medicines or an upcoming procedure? Those are better questions than “Does it thin blood?” - a phrase that skips over both the unproved benefit and the possible harm.
And there are moments when the appointment shouldn’t wait. Chest pain, sudden weakness or trouble speaking, severe breathlessness, a suspected leg or lung clot, uncontrolled bleeding, black stools, fainting or a sudden severe headache needs urgent medical evaluation, not a supplement trial. (FDA medication-and-supplement safety advice; MSKCC safety notes)
Bottom line: the small blood-pressure signal is worth further study. The clotting-marker changes are not proof that nattokinase prevents cardiovascular events, and the longer artery trial didn’t find the benefit the pitch implies. Don’t swap it for treatment or add it to a clot-affecting regimen without a qualified clinician’s review. (2023 review; three-year trial; MSKCC)